NEW YORK-- Shares of Celgene traded higher Thursday after a UBS analyst upgraded the biotechnology company, forecasting strong net income growth. He said Celgene's earnings and margins compare favorably to other health care companies.» Read More
Genentech's blockbuster cancer drug Avastin faces a big challenge from ImClone Systems's Erbitux in lung cancer, Morgan Stanley analysts said on Monday, citing unpublished data.
Genentech reported earnings that edged forecasts, but sales of all four of its big brand-name drugs fell short of forecasts.
Genentech stock is on a tear this year and analysts are expecting double-digit sales growth for most of the biotech's key drugs this quarter. Can Genentech keep it up?
Takeda Pharmaceutical said it would buy U.S. firm Millennium Pharmaceuticals for $8.8 billion to boost its cancer drug business, in the biggest overseas acquisition by a Japanese drug maker.
He's expecting a full recovery – and more – for this company.
Pfizer and Nektar Therapeutics said Wednesday clinical trials of the inhaled insulin Exubera found increased cases of lung cancer, leading Nektar to end talks with potential partners to market the product.
CEO Fred Hassan updates investors on his company's plans to rebound from the Vytorin debacle.
Options activity is picking up in Johnson & Johnson stock. Why?
Your kid is bulging. His name is Mark. He doesn't want to talk about the past. He forgets the English language. He starts misremembering things. You suspect he might be up to something. So what do you do? Until now, your options would be limited.
Walgreen posted a 4.4 percent increase in sales at stores open at least a year as strong demand for Easter merchandise helped offset tepid sales growth for prescription drugs.
Pfizer said on Tuesday it was halting a late stage study of its experimental drug for advanced melanoma after data showed it was no better than standard chemotherapy.
A drug commonly used to fight AIDS appears to nearly double the risk of a heart attack, researchers said Tuesday.
"We stand behind our product," Fred Hassan says. But does Cramer?
Celebrex risky in high-risk heart patients, study finds
Washington won't admit it, but they want a weak dollar. Here's the play.
Shares of Schering-Plough and Merck tumbled on Monday after doctors at a prominent medical meeting recommended patients try older cholesterol drugs before the companies' newer medicines.
AstraZeneca is stopping a clinical trial of its blockbuster cholesterol fighter Crestor early because of the clear benefits of the medicine compared to placebo, the company said on Monday.
In the absence of evidence that the cholesterol fighter Vytorin works better than a cheaper drug known as a statin, patients should turn back to using statins and other proven drugs, an expert panel said on Sunday.
AMAG Pharma has a drug that could be a "game changer," Cramer says. Find out how.
U.S. researchers said on Friday they plan to expand the size of a major study to determine the heart benefits of the controversial cholesterol fighter Vytorin, which they said would delay results until 2012.